Beta Drugs Limited

BETA DRUGS CONCALL HIGHLIGHTS(H1 FY2024)

1. Branded sales grew in the first half year 19% compared to last year. Got 5 new corporate hospitals as customers in india. Today they have a presence in 90% of corporate hospitals in india.
2. Company to launch 2 new Ndds in next half year. Focusing to increase sales people in tier 2 & 3 cities (District hospitals & medical college)
3. Signed with more than 20 partners on a global market. Increased the regulatory team up to 50 members
4. After 2 to 3 years export will be the growth driver. Next year the EU gmp audit will be completed. Company also applied for eurasia audit for cs countries.
5. In Dermatology today they have 14 products and are planning to increase it up to 35 to 40 products. Also adding 2 senior persons for the dermatology division.
6. In the next 1 and half year planned to put own plant for dermatology & expecting to get 50 Cr own branded sales in dermatology in the next 3 to 4 years. All are B2C brands. Currently 120 medical advisors and planning to increase.
7. Dermatology business target – This year 8 crores. Next year aiming 15 crores. After that 50 crores.
8. Dermatology capex for 30 Cr. Including B2B AND B2C can do 100 Cr
9. In Non western Countries pharma demand is still strong that’s why beta believing good export revenue in upcoming years.
10. In oral side capacity utilisation 70 to 80% and injectable side utilisation 50 to 60%. With current capacity can do 450 to 500 Cr.
11. After 2 to 3 years planning for Separate R & D lab for tech transfer & api and new injectable facility for USA.
12. Working Capital days by overall 85. Inventory days increased by 10.
13. In Derma business company will reach 23 to 24% ebitda margins once it reaches 30 Cr own branded sales.
14. Beta has market share of 5% in domestic and plan to migrate mainboard by next march or May
15. The upcoming 2 ndds have a huge market in India and planned to take this in foreign market as well. One is haematology and another is cytotoxic.